Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy

Lung(2024)10.1007/s00408-024-00742-xSource: DataRank Database

Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy is a research paper published in Lung (2024). On theSindex it has a DataRank of 0.241. It has been cited 4 times.

N/A

0.241DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.11)OA: hybridTopics (43)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.241

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (11)

Stefan Bentink,Christian Heßlinger,Thomas B. Leonard ORCID,Megan L. Neely ORCID,Nina Patel ORCID

Live enrichment

PubMed:39242435 PMC:PMC11427488 OpenAlex:https://openalex.org/W4402305722

The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc and run in collaboration with the Duke Clinical Research Institute and enrolling centers.

FWCI

1.11

Citation Percentile

0.8%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://link.springer.com/content/pdf/10.1007/s00408-024-00742-x.pdf

HYBRIDhttps://link.springer.com/content/pdf/10.1007/s00408-024-00742-x.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00408-024-00742-x.pdf

publisherhttps://link.springer.com/article/10.1007/s00408-024-00742-x/fulltext.html

journalhttps://doi.org/10.1007/s00408-024-00742-x

Fields of Study

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related DiseasesLung Cancer Treatments and MutationsMedicineHumansIdiopathic Pulmonary FibrosisMaleFemaleAgedMiddle AgedLung TransplantationRisk AssessmentAntifibrotic AgentsDisease ProgressionRegistriesRisk FactorsPulmonary Diffusing CapacityGene Expression Profiling

MeSH Terms

Antifibrotic AgentsAgedFemaleHumansMaleMiddle AgedPulmonary Diffusing CapacityRegistriesRisk FactorsLung TransplantationDisease ProgressionRisk AssessmentGene Expression ProfilingIdiopathic Pulmonary Fibrosis

Keywords

MedicineIdiopathic pulmonary fibrosisInternal medicineFibrosisPulmonary fibrosisOncologyLungPrognosisGene expression profilingObservational StudyInterstitial Lung Diseases

Sustainable Development Goals

SDG 0: Good health and well-being

Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy

FAIR Checklist

DataRank Breakdown

Authors (11)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)